Akorn names new exec, appoints two to board

LAKE FOREST - Akorn Inc. announced Christopher C. Young has joined the company s Executive Vice President, Global Operations.

In addition, Akorn President & Chief Executive Officer Douglas Boothe and Thomas G. Moore will join the pharmaceutical company's board of directors.

Young brings 25 years of pharmaceutical experience to Akorn, having most recently been the Executive Vice President of Global Operations for Alvogen, Inc. Prior to Alvogen, Young was Vice President of Operations in the United States and India for Actavis. He brings to Akorn a strong history of U.S. and global expertise in operations, supply chain, integration, remediation and operational excellence. His leadership and skills are well matched for the current challenges that the Company is facing with increased competition and a complex regulatory landscape. Young received his undergraduate degree from Gettysburg College and his MBA from Rutgers University.

Moore brings 35 years of strategic and operational pharmaceutical industry experience as a former executive at Abbott Laboratories, later known as Hospira, and its affiliates. Moore served as President of Hospira USA from 2009 until his retirement in 2014. He was President of Global Pharmaceuticals for Hospira Worldwide, Inc. from 2007 to 2009, and served as VP and General Manager of Specialty Pharmaceuticals for Hospira, Inc. from 2003 to 2007. Moore received his undergraduate degree from Loyola Marymount University Los Angeles, and his Doctor of Pharmacy from the University of Southern California.